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Abstract
Background: This study was aimed to explore the molecular mechanisms of hypertensive nephropathy (HTN).
Methods: Gene expression profile of GSE37460, which based on 27 healthy living donor samples (HTN group) and
15 hypertensive nephropathy samples (control group), were downloaded from Gene Expression Omnibus (GEO)
database. The differentially expressed genes (DEGs) between two groups were identified. STRING database was
used to reveal protein-protein interaction (PPI) network of DEGs, followed by the functional enrichment analysis of
the PPI network. Additionally, miRNA-DEG regulatory network was constructed to reveal the validated miRNAs
targeting the DEGs.
Results: In total, 51 up-regulated genes and 140 down-regulated genes were obtained. In the PPI network,
cytochrome P450 3A4 (CYP3A4) and angiotensin II receptor type 1 (AGTR1) had a higher degree, and CYP3A4
interacted with CYP4A11. The DEGs in the network were significantly enriched in drug metabolism, focal adhesion
and arachidonic acid metabolism. Furthermore, in the miRNA-DEG regulatory network, hsa-miR-335-5p and hsa-
miR-26b-5p were the two most outstanding miRNAs. AGTR1, CYP3A4 and CYP4A11 were predicted to be regulated
by hsa-miR-26b-5p.
Conclusion: The DEGs, such as AGTR1, CYP3A4 and CYP4A11 may play critical roles in the development of HTN
likely via the regulation by hsa-miR-26b-5p and taking part in some pathways.
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Background
Hypertensive nephropathy (HTN) is a kind of the
kidney injury due to chronic high blood pressure [1].
Hypertension-induced renal damage is an increasingly
common disease recently, and approximately 25 % of
patients currently treated with dialysis are hypertensive
before renal replacement therapy started [2]. Although the
antihypertensive drugs like cilnidipine (2-methoxyethyl
cinnamyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyri-
dine-3,5-dicarboxylate) and avosentan (N-[6-methoxy-
5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-
5-methylpyridine-2-sulfonamide) are commonly used
for the treatment of HTN [3, 4], the effect of clinical
treatment for HTN is still not ideal [5]. Due to the
increasing morbidity and mortality of renal disease,
molecular mechanisms of HTN are urgently required
to be revealed, which contributes to the improvement
of therapeutic strategies to control blood pressure
and delay progression of HTN [6].
Recently, the studies based on gene or protein investi-
gation are successfully used to reveal the potential
mechanisms of HTN. For instance, using distinct lines
of the spontaneously hypertensive rat, Dmitrieva et al.
have shown a major change in transcriptional control
by hepatocyte nuclear factor 1 that affects pathways
like redox and other genes, which further lead to the
hypertensive renal injury [7]. Periostin, also called
osteoblast-specific factor 2, strongly associated with
plasma creatinine, proteinuria and renal blood flow,
has been identified as a critical marker of progression
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and regression in HTN [8]. Moreover, SMAD family
member 7 has also been discovered to inhibit AngII-
mediated HTN through the Sp1/SMAD family member
3/nuclear factor kappa B (NF-κB)/miR-29b regulatory
network, and it is identified as a therapeutic biomarker for
AngII-mediated HTN [9]. Furthermore, the role of micro-
RNAs (miRNAs) in HTN has also been investigated in re-
cent years. A set of miRNAs (e.g. miR-429, miR-200a,
miR-205, miR-200b, miR-141, and miR-192) have been
found to be highly expressed in hypertensive nephro-
sclerosis, and the degree of upregulation is closely related
to disease severity [10]. Hsa-miR-181a has confirmed to
regulate REN (renin) and apoptosis-inducing factor,
mitochondrion-associated, 1 mRNA, and modulate REN
expression in HTN [11]. Using a mRNA expression profil-
ing dataset GSE37460, Berthier et al. have discovered a
series of pathways, such as endothelial cell activation/in-
jury, immune cell infiltration/activation, and tissue remod-
eling/fibrosis, with macrophage/dendritic cell activation in
both murine models and human lupus nephritis, and they
have also found that nuclear factor κB1 and peroxisome
proliferator-activated receptor γare major regulatory
nodes in the tubulointerstitial and glomerular networks
[12]. However, the differences between human HTN and
healthy controls remain unclear, and more genes and
pathways associated with HTN have not been found.
In the present study, based on the expression profile
data of healthy living donor samples and HTN samples
deposited by Berthier et al. [12], a bioinformatics ana-
lysis was performed. After identification of differentially
expressed genes (DEGs) and functional enrichment ana-
lysis of the DEGs, protein-protein interactions (PPIs) of
the DEGs were analyzed. Furthermore, miRNAs that
regulate DEGs were further investigated. These results
may contribute to a better understanding of the molecu-
lar mechanisms of HTN pathogenesis, and provide valid
biological information for further investigation of HTN.
Methods
As the study did not involve any human or animals, the
ethical approval was not required.
Affymetrix microarray data
The mRNA expression profile of GSE37460 [12] was
downloaded from a public functional genomics data
repository GEO (Gene Expression Omnibus, http://
www.ncbi.nlm.nih.gov/geo/), which was based on two
platforms, including Affymetrix Human Genome U133
Plus 2.0 Array (GPL11670) and Affymetrix GeneChip
Human Genome HG-U133A Custom Array (GPL14663)
(Affymetrix, California, USA). Glomeruli from kidney
biopsy samples from 27 healthy living donors (control
group), 15 hypertensive nephropathy (HTN group) and 25
IgA nephropathy (IgAN group) participants were included
in this profile. To explore the abnormal transcription
of HTN, the samples from HTN group and healthy
control group were specially enrolled for the follow-
ing investigation.
The data in the CEL source files were normalized
by using the R package CONOR [13], including back-
ground correction, quantile normalization and probe
summarization.
Identification of DEGs
The DEGs between control group and HTN group were
analyzed by using the Linear Models for Microarray
Data (LIMMA, http://www.bioconductor.org/packages/
release/bioc/html/limma.html) package in Bioconductor
software [14]. The raw p-value of each gene was adjusted
into the false discovery rate (FDR) by using Bonferroni
correction [15]. Only the genes with FDR-value < 0.05
and |log2FC (fold change)| ≥ 1.5 were identified as DEGs.
Construction of PPI network
The Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) database includes known and pre-
dicted PPIs [16]. The interactions of proteins encoded
by DEGs were selected as the background network ac-
cording to STRING v9.1 database with combined score >
0.9. Degree (the number of interactions linked to one tar-
get) was used to describe the frequency of interactions.
Subsequently, the DEGs and related first neighbors were
further extracted to construct the PPI network, which was
visualized by Cytoscape (http://www.cytoscape.org/) [17].
Functional enrichment analysis of pathways for genes in
the PPI network
The plugin in Cytoscape software, ClueGO, can integrate
Gene Ontology (GO) terms and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways to create a func-
tionally organized network [18]. By calculating the kappa
coefficient [19], the functional pathways can be divided
into several function groups in the network. To reveal
the biological functions of genes in the PPI network, the
KEGG pathway enrichment analysis for DEGs in the PPI
network was performed based on ClueGO. The raw
p-value of each pathway term was adjusted into the
FDR by using Bonferroni correction [15]. FDR-value <
0.05 was considered as the cutoff criterion of signifi-
cant difference, and pathway groups were generated
based on kappa = 0.4.
Analysis of miRNA regulation factor
The multiMiR (http://multimir.ucdenver.edu/) is an in-
tegration of miRNA-target interactions in R package and
database [20]. MultiMiR includes 3 validated miRNA-
target databases (miRecords, miRTarBase and TarBase),
8 predicted miRNA-target databases (miRDB, PicTar,
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DIANA-microT, ElMMo, PITA and TargetScan) and 3
disease- and drug-related miRNA databases (miR2Di-
sease, PharmacomiR and PhenomiR). In the present




A large number of calculations were performed, and the
original data were analyzed and filtered. A total of 51
up-regulated DEGs and 140 down-regulated DEGs were
obtained with thresholds of FDR < 0.05 and |log2FC| ≥
1.5. The heat map of DEGs showed that the HTN sam-
ples were distinguished clearly from the healthy samples
by the identified DEGs (Fig. 1).
PPI network investigation and functional enrichment
analysis
With the combined score > 0.9, a total of 1220 nodes
(36 up-regulated, 88 down-regulated and 1096 non-
significant ones) were included in the PPI network
(Fig. 2). The average degree for all enrolled DEGs was
14.5. The genes with nodes degree value > 50 [e.g. cyto-
chrome P450 family 3 subfamily A member 4 (CYP3A4)
and angiotensin II receptor type 1 (AGTR1)] were
listed in Table 1.
Furthermore, with FDR < 0.05 and kappa = 0.4, the
KEGG pathways enriched by DEGs in the present PPI
network were performed based on ClueGO (Fig. 3).
The DEGs were significantly enriched in pathways,
such as drug metabolism [e.g. CYP3A4 and alcohol de-
hydrogenase 1A (class I), alpha polypeptide (ADH1A)],
focal adhesion [e.g. collagen type IV alpha 1 (COL4A1)],
and arachidonic acid metabolism [e.g. cytochrome
P450 family 2 subfamily B member 6 (CYP2B6) and
cytochrome P450 family 4 subfamily A member 11
(CYP4A11)] (Table 2).
The miRNA-DEG regulatory network investigation
To study the validated miRNAs of DEGs, the miRNA-
DEG regulatory network was constructed based on mul-
tiMiR software. A total of 217 nodes (103 miRNAs, 34
up-regulated DEGs and 80 down-regulated DEGs) and
295 interactions were included in this network (Fig. 4).
Among the miRNAs, hsa-miR-335-5p and hsa-miR-26b-
5p modulated the majority of DEGs in this network. For
example, hsa-miR-26b-5p regulated COL4A1, CYP4A11
and AGTR1.
Fig. 1 Heat map for the differentially expressed genes. Each row represents a single gene; each column represents a tissue sample. Green blocks
represent the downregulated differentially expressed genes; red blocks represent the upregulated differentially expressed genes; black blocks
represent non-significant genes; light blue represents the control group, while pink represents hypertensive nephropathy group
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Discussion
HTN is an increasingly common kidney disease in pa-
tients with hypertension recently [6]. However, the po-
tential mechanisms of the progress of HTN is still
unclear. In this study, a bioinformatics analysis of gene
expression profile for healthy living donor samples and
HTN samples was performed to explore the mechanisms
of HTN. In total, 51 up-regulated DEGs and 140 down-
regulated DEGs were identified in the HTN samples
compared with the healthy controls. The DEGs were
significantly enriched in pathways like drug metabol-
ism, focal adhesion and arachidonic acid metabolism.
Furthermore, in the miRNA-DEG regulatory network,
hsa-miR-335-5p and hsa-miR-26b-5p were the two
most outstanding miRNAs.
In the present study, CYP3A4 and AGTR1 were the
outstanding down- and up-regulated DEGs with the
highest degree in the PPI network, respectively. CYP3A4
encodes an enzyme belonging to the cytochrome P450
(CYP P450) superfamily, which is a group of heme-
thiolate monooxygenases and participate in a variety of
oxidation reactions [21]. CYP P450 expression can be
altered by inflammation [22], which is involved in renal
injury [23]. The expression of CYP3A4 is induced by
Fig. 2 Protein-protein interaction network consisting of differentially expressed genes and non-significant genes. White diamonds represent the
down-regulated genes; white round nodes represent the up-regulated genes; gray round nodes represent the non-significant genes. The node
size is proportional to the degree value
Chen et al. BMC Nephrology  (2016) 17:149 Page 4 of 8
glucocorticoids and involved in the metabolism of mul-
tiple drugs [24]. A previous study has reported that
CYP3A4 T16090C SNP responses to amlodipine among
African-Americans with early HTN [25]. Moreover, the
expression of CYP3A4 is elevated in patients with end-
stage renal disease [26]. CYP4A11, a homologue of
CYP3A4, had a higher degree in the PPI network and
interacted with CYP4A11. In this study, CYP4A11 was
significantly enriched in the pathway of arachidonic acid
metabolism. CYP P450 metabolites of arachidonic acid
play an important role in the control of blood pressure,
chronic kidney disease through the maintenance of the
glomerular permeability barrier to albumin [27, 28].
Furthermore, 20-hydroxyeicosatetraenoic acid (20-HETE)
has renoprotective actions in hypertension, and mutations
Fig. 3 KEGG pathway enrichment analysis for differentially expressed genes in protein-protein interaction network. Each node is a KEGG pathway
item, and node size is proportional to the pathway significance. Edge between nodes mean that they share common genes, and the width of
the edge is proportional to the number of common genes. Pathways are classified into several functional groups (different node color) accordance
with the kappa value. The most significant pathway of each group labels with a highlighted color. KEGG, Kyoto Encyclopedia Of Genes And Genomes
Table 1 The up- and down-regulated differentially expressed genes
in the protein-protein interaction network (degree > 50 are listed)
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Table 2 The result of the most significant KEGG pathway in each functional group
ID Pathway name Count p-value FDR Genes
00982 Drug metabolism 60 8.02E-43 1.93E-40 CYP3A4, ADH1A, FMO1, GSTA1, MAOA …
00350 Tyrosine metabolism 29 1.36E-19 3.19E-17 ADH1A, COMT, DBH, FAH, GOT1…
04510 Focal adhesion 79 3.98E-18 9.23E-16 ACTN1, ACTN2, COL4A1, EGF, VWF…
00010 Glycolysis/Gluconeogenesis 38 4.46E-16 1.02E-13 ACSS1, DLAT, ENO2, FBP1, HK1…
05146 Amoebiasis 49 6.08E-15 1.38E-12 ACTN1, CD14, FN1, IL10, TNF…
00590 Arachidonic acid metabolism 35 8.03E-15 1.81E-12 ALOX12B, CYP2B6, CYP2B6, GGT1, CYP4A11…
00280 Valine, leucine and isoleucine degradation 29 6.82E-14 1.53E-11 AACS, DLD, EHHADH, IL4I1, PCCB…
00410 beta-Alanine metabolism 21 1.48E-11 3.22E-09 ABAT, ACADM, DPYD, EHHADH, UPB1…
00051 Fructose and mannose metabolism 20 8.95E-10 1.87E-07 AKR1B1, FBP1, HK1, MPI, PFKFB1…
05144 Malaria 22 2.04E-07 3.90E-05 CCL2, HGF, ICAM1, MET, VCAM1…
04020 Calcium signaling pathway 47 1.59E-05 0.002881 ADCY2, BDKRB1, AGTR1, EDNRA, F2R…
KEGG Kyoto Encyclopedia of Genes and Genomes, FDR false discovery rate. The p-value is adjusted into FDR using the Bonferroni correction
Fig. 4 The microRNA-differentially expressed gene regulatory network. White triangles represent microRNAs; white ellipses represent the up-regulated
genes; grey ellipses represent the down-regulated genes
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in CYP4A11 that produces 20-HETE have been linked
to elevated blood pressure in humans [29, 30], indi-
cating the important role of CYP4A11 in HTN. In the
present study, CYP4A11 was predicted to be regulated
by hsa-miR-26b-5p. An recent study has demon-
strated that expression of miR-26b-5p is significantly
decreased in basal serum samples from those patients
with acute kidney injury, and it is a diagnostic biomarker
of acute kidney injury [31]. Currently, there is no any
other evidence to prove the associations of CYP3A4,
CYP4A11 and hsa-miR-26b-5p with HTN. Given the
above studies, we speculated that CYP3A4 and CYP4A11,
as well as hsa-miR-26b-5p may play pivotal roles in the
progress of HTN.
AGTR1 also had a higher degree in the PPI network,
and it was modulated by hsa-miR-26b-5p. AGTR1 en-
codes of angiotensin II type 1 receptor, which is an
important effector in the control of blood pressure
[32]. Previous studies have shown that variants on
genes including AGTR1 are associated with hypertension
[33, 34]. The (−535) T allele of AGTR1 is believed to in-
crease hypertension risk among African Americans [35].
Moreover, AGTR1 polymorphisms are believed to be asso-
ciated with the renal function [36, 37]. Durvasula et al.
have reported that intrarenal production of angiotensin II
plays an important role in mediating HTN through indu-
cing podocyte injury and promoting the development of
glomerulosclerosis [38]. Furthermore, a previous study
has found that angiotensin II-induced arterial hyperten-
sion and vascular dysfunction are mediated by lysozyme
M–positive monocytes [39], which participate in renal
injury [40]. Although there is no direct evidence to
prove the association of AGTR1 and HTN, we speculate
that AGTR1 may exert critical functions in the progress
of HTN.
However, this study has several limitations. The major
limitation is that the aforementioned results should be
validated by other microarray data or experimental stud-
ies, which will be conducted and reported later. Further-
more, more patients with HTN should be included for
the analysis. Additionally, the clinical data of the patients
are not available, thus the patients may be heterogenous.
In the further study, more samples from patients with
HTN will be used for the verification experiments to
confirm our results.
Conclusion
In conclusion, 51 up-regulated DEGs and 140 down-
regulated DEGs were identified in the HTN samples
compared with the healthy controls. The DEGs such as
CYP3A4, CYP4A11 and AGTR1, may be crucial in the
progress of HTN, via the regulation by miRNAs (e.g. hsa-
miR-26b-5p) and participation in the biological pathways
(e.g. arachidonic acid metabolism). Notably, the above
discussed genes and miRNA are new-found to be corre-
lated with HTN in this study, and they are worth further
investigation. These findings provide new information for
further experimental studies. If these genes and miRNAs
are confirmed by experiments, they will be promising to
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